Nektar Therapeutics (STU:ITH) Other Income (Expense) : €23.63 Mil (TTM As of Dec. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Nektar Therapeutics Other Income (Expense)?

Nektar Therapeutics's other income expense for the Nektar Therapeutics's pretax income for the three months ended in Dec. 2024 was €37.15 Mil. Its other income expense for the trailing twelve months (TTM) ended in Dec. 2024 was €23.63 Mil.

Nektar Therapeutics Other Income (Expense) Historical Data

The historical data trend for Nektar Therapeutics's Other Income (Expense) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nektar Therapeutics Other Income (Expense) Chart

Nektar Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Other Income (Expense)

Get a 7-Day Free Trial

-37.15

-28.85

-96.87

-123.53

23.24

Nektar Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Other Income (Expense)	Get a 7-Day Free Trial															-8.44	-0.99	-12.38	-0.15	37.15

Nektar Therapeutics Other Income (Expense) Calculation

Other income expense includes minority interest. Minority interest is a significant but non-controlling ownership of less than 50% of a company's voting shares by either an investor or another company.

Other Income (Expense) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €23.63 Mil.

Nektar Therapeutics (STU:ITH) Other Income (Expense) Explanation

Minority interest is reported on the consolidated income statement as a share of profit belonging to minority shareholders.

Nektar Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nektar Therapeutics (STU:ITH) » Definitions » Other Income (Expense)

Comparable Companies

Traded in Other Exchanges

NKTR:USA NKTR:Mexico ITH:Germany

Address

455 Mission Bay Boulevard South, San Francisco, CA, USA, 94158

Website

https://www.nektar.com

Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company focused on discovering and developing medicines in the field of immunotherapy. The company is focused on discovering and developing medicines in the field of immunotherapy. Its pipeline products are REZPEG (NKTR-358), REZPEG (NKTR-358), REZPEG (NKTR-358), NKTR-422, NKTR-0165, NKTR-255, and Others.

Nektar Therapeutics Headlines

No Headlines